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Editor: Mohandas NarlaEfﬁcacy and safety of iron chelation therapy with deferasirox in iron-overloaded non-transfusion-dependent
thalassaemia (NTDT) patients were established in the THALASSA study. THETIS, an open-label, single-arm,
multicentre, Phase IV study, added to this evidence by investigating earlier dose escalation by baseline liver
iron concentration (LIC) (week 4: escalation according to baseline LIC; week 24: adjustment according to LIC re-
sponse, maximum 30 mg/kg/day). The primary efﬁcacy endpoint was absolute change in LIC from baseline to
week 52. 134 iron-overloaded non-transfusion-dependent anaemia patients were enrolled and received
deferasirox starting at 10 mg/kg/day. Mean actual dose ± SD over 1 year was 14.70 ± 5.48 mg/kg/day. At
week 52, mean LIC ± SD decreased signiﬁcantly from 15.13 ± 10.72 mg Fe/g dw at baseline to 8.46 ± 6.25 mg
Fe/g dw (absolute change from baseline,−6.68 ± 7.02 mg Fe/g dw [95% CI:−7.91,−5.45]; P b 0.0001). Most
common drug-related adverse events were gastrointestinal: abdominal discomfort, diarrhoea and nausea
(n= 6 each). There was one death (pneumonia, not considered drug related).With signiﬁcant and clinically rel-
evant reductions in iron burden alongside a safety proﬁle similar to that in THALASSA, these data support earlier
escalation with higher deferasirox doses in iron-overloaded non-transfusion-dependent anaemia patients.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Non-transfusion-dependent thalassaemia (NTDT) describes a group
of inherited genetic disorders that affect haemoglobin (Hb) chain syn-
thesis, leading to ineffective erythropoiesis and anaemia [1–4]. NTDT
comprises several thalassaemia syndromes that do not require regular
blood transfusions for survival (transfusions may be required in some
instances, such as pregnancy, infection or growth failure), most com-
monly including β thalassaemia intermedia, Hb H disease and Hb E/β
thalassaemia [5]. Despite infrequent blood transfusions, patients with
NTDT are at risk of iron overload mainly because of increased iron up-
take from the gastrointestinal tract [6,7], as a result of ineffective eryth-
ropoiesis, accompanied by anaemia and hypoxia [8]. While thethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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overload and elevated liver iron concentration (LIC) in NTDT is similar
to patients with transfusion-dependent thalassaemia (TDT), including
abnormal liver function, ﬁbrosis and cirrhosis, as well as endocrine dis-
orders [9–12].
Clinical studies have provided evidence for the efﬁcacy and safety of
iron chelation therapy in NTDT patients with iron overload [13–19].
The THALASSA study was the ﬁrst randomised, placebo-controlled
study demonstrating the efﬁcacy and safety of deferasirox (Exjade®,
Novartis Pharmaceuticals) in a large cohort of NTDT patients [19–22].
In the 1-year THALASSA study, deferasirox was initiated at doses of 5
and 10 mg/kg/day and increased to 10 and 20 mg/kg/day at month 6.
Deferasirox 10mg/kg/day demonstrated signiﬁcantly improved efﬁcacy
over the 5 mg/kg/day regimen in reducing LIC, and nearly half of
all patients required dose escalations up to 20 mg/kg/day. These
ﬁndings indicated that a higher chelation dose may be required and
should be initiated earlier in the course of treatment to achieve a
more rapid reduction in iron burden. Both deferasirox starting doses
and placebo groups had a similar safety proﬁle and incidence of
adverse events (AEs) [19]. Based on these outcomes, the Thalassaemia
International Federation guidelines recommend iron chelation
therapy with deferasirox in NTDT patients ≥10 years of age when
LIC reaches ≥5 mg Fe/g dw (or serum ferritin ≥800 ng/mL), starting at
10 mg/kg/day. After 6 months of treatment, the dose may be escalated
to 20 mg/kg/day in patients with LIC N7 mg Fe/g dw (or serum ferritin
levels 1500–2000 ng/mL if LIC measurement is unavailable) and b15%
reduction in baseline values [23].
Here we report 1-year data from the THETIS study, a Phase IV, open-
label, multicentre efﬁcacy and safety study of deferasirox in iron-
overloaded patients with NTDT. This study adds to existing knowledge
by assessing a broader patient population through allowing inclusion
of patientswith non-transfusion-dependent congenital or chronic anae-
mias in addition to the non-transfusion-dependent thalassaemias also
studied in THALASSA (β thalassaemia intermedia, Hb E/β thalassaemia
orα thalassaemia intermedia [HbH] disease), concomitantmedications
commonly used in the treatment of NTDT syndromes, and by investigat-
ing earlier dose escalation according to baseline LIC and every 6months
according to LIC.
2. Methods
2.1. Key inclusion/exclusion criteria
Patients ≥10 years of age with non-transfusion-dependent congeni-
tal or chronic anaemias and iron overload (LIC measured by R2 mag-
netic resonance imaging [MRI] ≥5 mg Fe/g dw) and serum ferritin
≥300 ng/mL at screening were recruited. Ancillary treatments for
NTDT, such as hydroxyurea, were allowed. Exclusion criteria included:
blood transfusions within 6 months of study enrolment or anticipated
regular transfusions (unplanned transfusions were allowed), Hb S
variants of thalassaemia, active hepatitis B or C, cirrhosis, history of clin-
ically relevant ocular and/or auditory toxicity related to iron chelation
therapy, or on two consecutive measurements: alanine aminotransfer-
ase (ALT) N 5× the upper limit of normal (ULN), serum creatinine
(SCr) N ULN, creatinine clearance (CrCl) ≤ 40 mL/min, or urine
protein/urine creatinine ratio (UPCR) N 1.0 mg/mg. Paediatric patients
had to weigh at least 20 kg. Patients (or parents/guardians) provided
written, informed consent prior to enrolment.
2.2. Study design
THETIS is an open-label, single-arm, multicentre, Phase IV, 5-year
study with the primary endpoint after 52 weeks of treatment. The
starting deferasirox dose was 10 mg/kg/day, with dose increases
permitted at week 4 (maximum dose of 20 mg/kg/day) and week 24
(maximum dose of 30 mg/kg/day; Fig. 1), selected based on the resultsfrom the THALASSA study. Dose decreases according to safety assess-
ments were performed in increments of 5 mg/kg/day to a minimum
of 5 mg/kg/day. If repeated serum ferritin levels were b300 ng/mL
or LIC b 3 mg Fe/g dry weight (dw) at any visit, treatment was
suspended, then restarted at the previous effective dose (maximum 10
mg/kg/day) when serum ferritin increased to ≥300 ng/mL and LIC to
≥5mg Fe/g dw. The study was conducted in accordance with Good Clin-
ical Practice guidelines and theDeclaration of Helsinki andwas approved
by independent ethics committees at participating sites.
2.3. Assessments
The primary endpoint was the absolute change in LIC (mg Fe/g dw)
from baseline to 52 weeks, supported by analyses of the proportion of
patients with an absolute LIC reduction of at least 3 mg Fe/g dw or rela-
tive reduction of ≥30%. Secondary endpoints included mean absolute
change in LIC from baseline to 24 weeks, change in serum ferritin
from baseline to 52 weeks, and correlation of LIC with serum ferritin
at baseline and week 52.
LIC was assessed at screening, week 24 andweek 52 using validated
R2MRI (FerriScan®) [24]. Serum ferritin wasmeasured at screening, on
day 1 and every 4 weeks thereafter. LIC and serum ferritin were
analysed at a central laboratory.
Safety was evaluated by regular monitoring and recording of AEs
and serious AEs (SAEs), laboratory testing and clinical evaluations. Com-
pliancewas estimated based on the prescribed versus dose taken, calcu-
lated using the dose administration record.
2.4. Statistical evaluations
Assuming a standard deviation of 6mg Fe/g dw and drop-out rate of
20%, a sample size of 117 patientswas calculated to obtain 90% power to
detect an absolute change in LIC of ≥2mg Fe/g dw frombaseline toweek
52, using a two-sided paired t-testwith 5% signiﬁcance level. The prima-
ry efﬁcacy analysis utilised the full analysis set (all patients assigned
study drug). If no LIC measurement was available at week 52, the last
available post-baseline LIC measurement before week 52 was used
(last observation carried forward [LOCF]). The null hypothesis (change
from baseline to week 52 equal to 0) was tested against the alternative
hypothesis. LIC change from baseline to week 24 and serum ferritin
change from baseline to week 52 were analysed as secondary objec-
tives. Correlation analyseswere performed for paired LIC and serum fer-
ritin values.
3. Results
3.1. Patient demographics and clinical characteristics
A total of 134 patients enrolled between 6 December 2012 and 22
November 2013; 112 (83.6%) completed 1 year of treatment. Patients
discontinued treatment because of withdrawal of consent (n = 10,
noted as personal or logistical reasons), loss to follow-up (n= 4), preg-
nancy (n= 4) and other reasons (death, AE, protocol deviation and pa-
tient decision, n = 1 each). The majority of patients received prior
intermittent transfusion therapy (85.8%) and had elevated baseline
mean LIC ± standard deviation (SD) and median serum ferritin levels;
47.8% of patients received prior chelation therapy (Table 1).
3.2. Exposure to treatment and compliance
The mean actual deferasirox dose ± SD received during the 1-year
study (considering dose adjustments) was 14.70 ± 5.48 mg/kg/day
over a mean duration of 11.57 ± 2.68 months. Over 1 year, 124
(92.5%) patients received dose adjustments according to the protocol,
including restarts (n = 53, 39.6%), to achieve LIC b 3 mg Fe/g dw
(n = 15, 11.2%) and serum ferritin b 300 ng/mL (n = 10, 7.5%). AEs
Fig. 1. Deferasirox dosing algorithm. LIC is measured in mg Fe/g dw; deferasirox dose is measured in mg/kg/day; serum ferritin is measured in ng/mL. dw, dry weight; LIC, liver iron
concentration.
Table 1
Patient demographic, disease and baseline characteristics.
Variable All patients (N = 134)
Disease, n (%)
β thalassaemia intermedia 69 (51.5)
Hb H diseasea 40 (29.9)
Hb E/β thalassaemia 24 (17.9)
Congenital dyserythropoietic anaemia 1 (0.7)
Mean age ± SD, years 28.0 ± 11.1
Median age (range), years 27 (10–63)
Paediatric patients (10–b18 years), n (%) 25 (18.7)
Male:female, n 76:58
Race, n (%)
Asian 85 (63.4)
Caucasian 47 (35.1)
Other 2 (1.5)
Splenectomy, n (%) 77 (57.5)
Prior transfusions received, n (%) 115 (85.8)
Previous chelation, n (%) 64 (47.8)
Deferoxamine 18 (13.4)
Deferiprone 17 (12.7)
Deferasirox 29 (21.6)
Mean LIC ± SD 15.13 ± 10.72
Median LIC (range) 11.35 (5.0–50.5)
LIC category, n (%)
5–≤7 36 (26.9)
N7–≤15 49 (36.6)
N15 49 (36.6)
Mean serum ferritin ± SD 1427 ± 1118
Median serum ferritin (range) 1001 (232–6638)
Serum ferritin category, n (%)
b300 1 (0.7)b
≥300–≤500 17 (12.7)
N500–≤1000 49 (36.6)
N1000–≤2500 51 (38.1)
N2500–≤5000 14 (10.4)
N5000 2 (1.5)
LIC is measured in mg Fe/g dw; serum ferritin is measured in ng/mL.
dw, dry weight; Hb, haemoglobin; LIC, liver iron concentration; SD, standard deviation.
a Hb H Constant Spring (−SEA/αCSα; n = 7), Homozygous Hb Constant Spring (αCSα/
αCSα; n = 2), deletional Hb H (−SEA/−α4.2; n = 1), triple alpha gene deletion (n = 1),
+861 G–A (n = 1),−/−α3.7 (n = 1), genotype unknown (n = 27).
b This patient was ineligible for inclusion, removed from the study and considered a
protocol deviation.
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tients; the principal causes were diarrhoea (n = 6, 4.5%) and vomiting
(n=5, 3.7%). The dosewas increased atweek 24 in 48 (38.7%) patients,
reduced in 30 (24.2%) patients and interrupted in two (1.6%) patients.
Between week 24 and week 52, dose increases were required in six
(5.4%) patients, 32 (28.8%) had dose reductions and 19 (17.1%) received
interruptions as per protocol. Overall, 22 (17.7%) and 10 (9.0%) patients
received the maximum daily dose of 30 mg/kg/day at week 24 and
week 52, respectively. Compliance with medication was high, with
97.1% of the planned doses taken.
3.3. Transfusions
The majority of patients did not receive transfusions during the
study (n = 112, 83.6%); seven (5.2%), ﬁve (3.7%), four (3.0%), one
(0.7%) and ﬁve (3.7%) patients received 1, 2, 3, 4 and N4 transfusions,
respectively.
3.4. Efﬁcacy of deferasirox
Mean LIC ± SD decreased signiﬁcantly from 15.13 ±
10.72 mg Fe/g dw at baseline to 8.46 ± 6.25 mg Fe/g dw at week 52
(absolute change from baseline,−6.68 ± 7.02 mg Fe/g dw [95% conﬁ-
dence interval (CI):−7.91,−5.45]; P b 0.0001). This is equivalent to a
change in total body iron of approximately−0.18mg/kg/day, based on
a formula [25] that accounts for iron accumulation in untreated NTDT
patients [19]. At the last assessment, an absolute decrease in LIC of
≥3 mg Fe/g dwwas observed in 86 (64.2%) patients, while a ≥30% rela-
tive reduction in LIC was observed in 81 (60.4%) patients. There was a
markedly greater absolute reduction in mean LIC at both week 24 and
week52 in patientswith higher baseline LIC (≥15mgFe/g dw),with pa-
tients receiving a highermean actual deferasirox dose (Table 2). Data by
serum ferritin subgroups ≥300–500, N500–1000 and N1000 ng/mL are
shown in Supplementary Table 1. Overall, the majority of patients
moved to a lower iron burden category by week 52 (66.9%; Table 3),
with 15 patients (12.7%) achieving LIC b 3 mg Fe/g dw; as such, treat-
ment was suspended.
Median serum ferritin (range) decreased from 1001 (232–6638)
ng/mL at baseline to 669 (200–4315) ng/mL at week 52 (absolute
Table 2
Change in LIC by baseline LIC at week 24 and week 52.
Baseline LIC
Mean ± SD
5–≤7
(n=36)
>7–≤15
(n=49)
>15
(n = 49)
Baseline LIC 6.06 ± 0.55 10.37 ± 2.46 26.56 ± 9.68
Week 24 LIC 4.90 ± 1.67 7.63 ± 3.06 19.97 ± 8.95
Week 24 absolute change in LIC –1.18 ± 1.53 –2.77 ± 2.11 –6.28 ± 4.53
Change in total body iron* –0.02 –0.07 –0.17
Deferasirox dose over 24 weeks 9.66 ± 0.82 13.26 ± 1.30 17.34 ± 1.79
Week 52 LIC 4.25 ± 1.63 5.72 ± 2.80 13.48 ± 7.23
Week 52 absolute change in LIC –1.82 ± 1.60 –4.49 ± 2.17 –13.64 ± 8.09
Change in total body iron* –0.04 –0.12 –0.39
Deferasirox dose over 52 weeks 8.95 ± 1.87 13.37 ± 2.90 20.27 ± 3.72
LIC is measured in mg Fe/g dw; deferasirox dose and change in total body iron are mea-
sured in mg/kg/day.
Patients includedhad a value at baseline and at the considered time point.Week 24 and 52
data are based on the last available LIC during days 2–198 and days 199–378, respectively.
dw, dry weight; LIC, liver iron concentration; SD, standard deviation.
a Estimated based on a formula [25] that took into account the mean rate of iron
accumulation in placebo-treated NTDT patients [19].
Fig. 2. LIC and serum ferritin assessments over time by baseline LIC categories. A) Mean
LIC ± SD; B) median serum ferritin ± 25th/75th percentiles. Patients included had a
value at baseline and at the considered time point. Week 24 and 52 LIC data are based
on the last available LIC during days 2–198 and days 199–378, respectively. dw, dry
weight; LIC, liver iron concentration; SD, standard deviation.
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duction in both LIC and serum ferritin was progressive over the course
of the study across all baseline LIC categories (Fig. 2A and B). There
was a moderate correlation between LIC and serum ferritin at baseline
(r= 0.730; Supplementary Fig. 1A) and at week 52 (r= 0.634; Supple-
mentary Fig. 1B). There was also a moderate correlation between abso-
lute changes in serum ferritin and LIC (r = 0.694; Fig. 3A), indicating a
reduction in both LIC and serum ferritin in the majority of patients. A
strong correlation was identiﬁed between change in LIC and baseline
LIC (r =−0.844; Fig. 3B).
3.5. Safety parameters
3.5.1. Adverse events
Investigator-reported AEs regardless of causality were reported in
97 (72.4%) patients andwere unaffected by average daily dose received.
AEs with a suspected relationship to deferasirox were reported in 42
(31.3%) patients and were predominantly gastrointestinal (Table 4).
Overall, during deferasirox treatment, eight patients received concomi-
tant hydroxyurea.
One patient was reported with a suspected SAE (pancreatitis) relat-
ed to study drug that lasted for 11 days; deferasirox was withheld for
the duration of this AE and then restarted. One patient discontinued
treatment because of an AE (extramedullary haematopoiesis), although
a relationship to deferasirox was not suspected. One death occurred
during the study as a result of pneumonia leading to cardiac failure;
this was not suspected to be related to study drug.
At week 52, three patients (baseline LICs of 30.1, 28.5 and
6.8 mg Fe/g dw), with unspeciﬁed clinically insigniﬁcant audiological
abnormalities detected during screening, developed clinicallyTable 3
Changes in iron overload status between baseline and week 52.
Week 52 LIC
Baseline LIC n (%)
b3,
n (%)
3–b5,
n (%)
5–7,
n (%)
N7–15,
n (%)
N15,
n (%)
n (%) 15 (12.7) 32 (27.1) 21 (17.8) 35 (29.7) 15 (12.7)
5–7 32 (27.1) 9 (28.1) 12 (37.5) 9 (28.1) 2 (6.3) 0
N7–15 44 (37.3) 5 (11.4) 18 (40.9) 8 (18.2) 13 (29.5) 0
N15 42 (35.6) 1 (2.4) 2 (4.8) 4 (9.5) 20 (47.6) 15 (35.7)
LIC is measured in mg Fe/g dw.
Bold indicates patients who moved to a lower iron burden range. Patients included had a
value at baseline and week 52 (last available LIC during days 199–378).
dw, dry weight; LIC, liver iron concentration.signiﬁcant audiological abnormalities noted as moderate sensorineural
hearing loss, moderate conductive hearing loss, and sensorineural hear-
ing loss, respectively. At week 52, these patients were receiving
deferasirox doses of 30, 25 and 10 mg/kg/day and LIC had changed to
12.5, 34.3 and 5.5 mg Fe/g dw, respectively. The ﬁrst two cases were re-
ported as AEs of special interest and as related to deferasirox. In the pa-
tient with sensorineural hearing loss (not suspected to be related to
deferasirox), large cupping and mild cortical cataract were also report-
ed, both of which were suspected to be related to deferasirox.
3.5.2. Laboratory parameters
One patient had an elevated baseline ALT 2 × ULN that increased to
N5 × ULN on one occasion; baseline bilirubin levels were 2 × ULN and
alkaline phosphatase 1.5 × ULN. Without dose adjustment or inter-
ruption, all parameters improved better than baseline values by week
52. No patient had two consecutive serum creatinine increases of
N33% above baseline and NULN. Two consecutive CrCl measurements
b60 mL/min were recorded in three patients, all with baseline levels
N60 mL/min. Of these three, two patients continued treatment without
dose adjustment and at week 52, CrCl was N60 mL/min in one patient
and remained b60mL/min in the other. The third patient's dosewas de-
creased from30 to 20mg/kg/day and atweek 52, CrCl was N60mL/min.
UPCR increased to N1.0 mg/mg on two consecutive measurements in
Fig. 3. Relationship between change in LIC versus A) change in serum ferritin at week 52
and B) baseline LIC. dw, dry weight; LIC, liver iron concentration.
Fig. 4. Serum creatinine and creatinine clearance over time by baseline LIC category.
A) Mean serum creatinine ± SE; B) mean creatinine clearance ± SE. dw, dry weight;
LIC, liver iron concentration; SE, standard error.
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interrupted for 2weeks, and UPCR decreased to ≤1.0mg/mg. Treatment
was restarted at 10mg/kg/day, and UPCR remained stable. Although re-
maining within the normal range, there was a trend for increasing SCr
and declining CrCl over time (Fig. 4A and B). Analysis by age group indi-
cated that patients b18 years old had twice the increase in the last avail-
able SCr measurements and a four-fold decrease in the last available
CrCl; there was also high intervariability from month to month. There
was no discernible relationship between baseline LIC categories and in-
creases in SCr or decreases in CrCl. Mean aminotransferase elevations
showed a decreasing trend over time and there were no progressive
changes in UPCR (Supplementary Fig. 2). No patient with notable
renal or liver laboratory values discontinued treatment.
Overall, 23 patients (17.2%) had notable reductions in absolute neu-
trophil count (ANC: b1.5 × 109/L after baseline); ANC was N1.0 toTable 4
Most common (≥2 patients) investigator-assessed drug-related AEs.
AE, preferred term, n (%) All patients (N = 134)
Abdominal discomfort 6 (4.5)
Diarrhoea 6 (4.5)
Nausea 6 (4.5)
Abdominal pain 5 (3.7)
Upper abdominal pain 5 (3.7)
Dyspepsia 3 (2.2)
Rash 3 (2.2)
Increased blood creatinine 2 (1.5)
Insomnia 2 (1.5)
Increased UPCR 2 (1.5)
Vomiting 2 (1.5)
Note: A patient with multiple occurrences of the same event is counted only once.
AE, adverse event; UPCR, urine protein/urine creatinine ratio.b1.5 × 109/L after baseline in 16 of these patients (eight of whom had
post-baseline infections), none had ANC b0.5 × 109/L and three had
ANC b 1.5 × 109/L at baseline. None of the infections represented a
new safety signal. Therewere no episodes of drug-induced neutropenia,
agranulocytosis or thrombocytopenia. Nine patients (6.7%) had notable
reductions in platelet count (b100 × 109/L after baseline; range
63–99 × 109/L).
4. Discussion
The 1-year analysis from THETIS provides further evidence to sup-
port the efﬁcacy and safety of initiating deferasirox 10 mg/kg/day,
escalating earlier at week 4 according to baseline LIC to a maximum of
20 mg/kg/day, then up to a maximum of 30 mg/kg/day according to
LIC response atweek 24 and every 6months thereafter. This dosing reg-
imen was selected based on the results from the THALASSA study,
which indicated improved efﬁcacy of 10 mg/kg/day as a starting dose,
escalated to 20 mg/kg/day to signiﬁcantly reduce LIC and serum ferritin
[19]. Hence, patientswith a higher baseline and ongoing iron burden re-
ceived correspondingly higher deferasirox doses. Treatment was ad-
ministered to patients with LIC ≥ 5 mg Fe/g dw, the threshold above
which there is a greater risk of iron-overload-related complications
[10,11,23]. Treatmentwaswithheld if LIC was b3mg Fe/g dwor repeat-
ed serum ferritin levels were b300 ng/mL, in order to reduce the risk of
over-chelation at normal body iron levels. The primary endpoint was
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line to week 52 (P b 0.0001), equivalent to a decrease in total body iron
of approximately 0.18mg/kg/day. The absolute change in LIC frombase-
line was strongly correlated with baseline LIC. The largest reductions in
LIC occurred in patients with greater iron overload at baseline, who had
also received higher average deferasirox doses. Furthermore, absolute
LIC reduction of ≥3 mg Fe/g dw or relative reduction of ≥30% were ob-
served in approximately 60% of patients.
Despite some differences in patient demographics and baseline iron
overload, with an earlier dose escalation and higher deferasirox doses
permitted in THETIS, the absolute reduction in LIC and serum ferritin
atweek 52was greater than that in THALASSA [19]. In THETIS,more pa-
tients achieved LIC b3mg Fe/g dw,mainly in patientswith a lower base-
line LIC. However, it can be speculated that more patients will achieve
this therapeutic target, irrespective of baseline LIC, on optimised treat-
ment as the study continues. Although doses up to 30 mg/kg/day
were permitted, most patients required the maximum dose for a rela-
tively short time before being titrated down.
Prior to the study, the majority of patients received intermittent
transfusions, which contributed to the development of iron loading in
combination with underlying ineffective erythropoiesis associated
with non-transfusion-dependent congenital and chronic anaemias.
With the known associations between iron overload and morbidity in
NTDT patients [10,11], the need for guidance in optimising chelation
therapy is apparent. These data support earlier dose escalation follow-
ing initiation of treatment, followed by further optimisation based on
response to chelation therapy as assessed by LIC. LIC assessment by
MRI is robust and recommended for the assessment of iron overload
in NTDT patients [23]. Results from THETIS and other published studies
[26–29] indicate a positive correlation between serum ferritin and LIC in
patients with NTDT, though with variable strengths of association.
THETIS also demonstrated that this correlation is maintained during
treatment with deferasirox. However, serum ferritin trends should not
be used to make treatment decisions when MRI analysis is available.
Safety data from THETISwere similar to safety ﬁndings in THALASSA
[19]. Despite higher deferasirox doses and use of concomitant treat-
ments, such as hydroxyurea, no new safety signals were identiﬁed.
Investigator-assessed drug-related AEs were predominantly gastroin-
testinal, as previously observed in both NTDT [19] and TDT [30] patients
treatedwith deferasirox. Although themajority of dose reductionswere
a result of AEs, the incidence of drug-related AEs (31.3%) was similar to
that observed in THALASSA (24.1%) [19] and considerably lower than
that reported in TDT patients (50.3%) [30]. The absence of progressive
changes over 1 year in renal and hepatic laboratory parameters was
consistent with previous observations [19], and there was a decreasing
trend in aminotransferases over time. Although remaining within nor-
mal limits, the slight trend of worsening SCr and CrCl over 1 year may
be a result of growth of paediatric patients with increasing muscle
mass who had notably increased SCr and correspondingly decreased
CrCl at the last available measurement in this 1-year study.
In conclusion, deferasirox effectively reduced iron overload in NTDT
patients at a starting dose of 10 mg/kg/day, with dose escalations from
week 4 according to baseline LIC and further dose adjustments up to
30 mg/kg/day according to LIC response. These ﬁndings will help to
guide physicians in optimising iron chelation therapy with deferasirox
in NTDT patients based on continuous monitoring with either LIC or
serum ferritin and to inform updates to treatment guidelines. The
THETIS trial is ongoing to provide long-term follow-up of NTDT patients
for up to 5 years.
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